Roche’s Elecsys pTau181 test has secured CE Mark approval, marking a development in ruling out Alzheimer's disease.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...

Ms. Korczynski joined Aquestive in February 2024 to lead the Company's sales and marketing initiatives. With more than two decades of commercial and launch experience across leadership roles at ANI ...

David Mooney, who most recently served as Chief of Cyber Protective Services at the Cybersecurity and Infrastructure Security ...

Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed pharmaceutical stocks on Cramer’s morning show.

Kade Anderson has emerged as the favorite to be selected No. 1 overall by the Washington Nationals in the 2025 MLB draft, but there is a possibility that high-school shortstop Eli Willits could ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:LLY), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

Cantor Fitzgerald cut Eli Lilly’s FY2025 earnings forecast from $21.91 to $21.76 per share. Eli Lilly reported $3.34 per share in Q1 2025, missing analysts’ consensus estimate of $4.64. Despite this, ...

NETSCOUT Earns Frost & Sullivan's 2025 MENA Technology Innovation Leadership Recognition for Excellence in Cybersecurity SolutionsNETSCOUT pioneers AI-driven cybersecurity and integrated network ...

The results represent the current state of operational technology (OT) cybersecurity and highlight opportunities for continued improvement for organizations to secure an ever-expanding IT/OT ...

Eli Lilly stock trades at $786.92 after the FDA approves a safer dosing label for Kisunla in early Alzheimer’s. Key trial data support the update.